Search clinical trials for: escalating doses

Total 3922 results

CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Disorders | Hb-SS Disease | Hemoglobin S | Disease Sickle Cell Anemia | Hemoglobin Beta Thalassemia Disease

United States
Biocad

Recruiting

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL) (BLUEBELL)

Spinal Muscular Atrophy (SMA)

Belarus, Russian Federation
Protalix

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Gout

New Zealand
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors

Advanced Solid Tumors
Oasis Pharmaceuticals, LLC
Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...

Recruiting

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
Naval Medical Research Center
The 108 Military Central Hospital; Naval Medical Research Unit TWO (NAMRU-2); Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI) and other collaborators

Not yet recruiting

Escalating Monthly Doses of Tafenoquine in Healthy Volunteers (TQ)

Prophylaxis

Vietnam
University of Illinois at Chicago

Recruiting

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (VEN-OM)

Relapsed or Refractory Hematologic Malignancies

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Loyola University
National Cancer Institute (NCI)

Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Melanoma

United States
Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
Noema Pharma AG

Completed

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Childhood-Onset Fluency Disorder

United States, Australia
Contineum Therapeutics

Completed

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Multiple Sclerosis

United States
Pfizer

Completed

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

United States
Biocad

Completed

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Healthy

Russian Federation
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

United States, Canada
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
Helen Reynolds
Desmond Tutu HIV Centre; Infectious Disease Institute, Kampala, Uganda

Active, not recruiting

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (DoRIS)

Tuberculosis | Hiv

Uganda, South Africa
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Telavant, Inc.
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Healthy

United States
Children's Hospital Los Angeles

Completed

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin (VIT-B)

Refractory Solid Tumors in Children

United States
M.D. Anderson Cancer Center

Completed

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Hackensack Meridian Health
Millennium Pharmaceuticals, Inc.

Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT (Thal/Mel/Vel)

Multiple Myeloma

United States
Shin Poong Pharmaceutical Co. Ltd.

Terminated

A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Ischemic Stroke | Atherosclerosis

United Kingdom
Genentech, Inc.

Completed

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Belgium, Australia, Denmark, Norway
GamaMabs Pharma

Completed

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

Neoplasm, Gynecologic

France, Belgium, United Kingdom
Pipeline Therapeutics, Inc.

Completed

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Multiple Sclerosis

Australia
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Canada, United States
AzurRx SAS

Completed

Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs

Cystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas

Turkey, Hungary
Navidea Biopharmaceuticals

Completed

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Arthritis, Rheumatoid

United States
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Belite Bio, Inc

Completed

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Terminated

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Breast Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Relapsed Lymphoid Malignancy | Refractory Lymphoid Malignancy

United States, Canada
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Healthy Volunteers

United States
Biocad

Completed

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Healthy

Russian Federation
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States, Canada
Merck Sharp & Dohme LLC
Pfizer

Completed

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Type 2 Diabetes Mellitus
Universitaire Ziekenhuizen KU Leuven

Completed

Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick

Pruritus

Belgium
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin (PER977)

Healthy

United States
ContraFect

Completed

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

United States
PharmaMar

Completed

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Neuroendocrine Tumors | Endometrial Adenocarcinomas | Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

Spain, United Kingdom

3

Subscribe